Literature DB >> 29420861

Do subjects with minimal motor features have prodromal Parkinson disease?

Yaping Chu1, Aron S Buchman1,2, C Warren Olanow3, Jeffrey H Kordower1,4.   

Abstract

OBJECTIVE: Understanding the pathological changes underlying mild motor features of the eldery and defining a patient population with prodromal Parkinson disease (PD) are of great clinical importance. It remains unclear, however, how to accurately and specifically diagnose prodromal PD. We examined whether older adults with minimal parkinsonian motor features have nigrostriatal degeneration and α-synuclein pathology consistent with prodromal PD.
METHODS: Brain sections were obtained from older adults with a clinical diagnosis of PD (n = 21) and without a clinical diagnosis of PD (n = 27) who underwent motor examination proximate to death. Cases without PD were further dichotomized into no motor deficit (n = 9) or minimal motor features (n = 18) groups using a modified Unified Parkinson's Disease Rating Scale. We performed quantitative unbiased stereological analyses of dopaminergic neurons/terminals and α-synuclein accumulation in the nigrostriatal system.
RESULTS: In all subjects with minimal motor features, there were significant reductions in dopaminergic neurons and terminals in the substantia nigra and putamen that were intermediate between subjects with no motor deficit and PD. Phosphorylated α-synuclein inclusions were observed in the substantia nigra that were of similar density to what was seen in PD. Furthermore, there was greater Lewy neuritic pathology in the putamen relative to PD patients. Lastly, neurons with α-synuclein inclusions displayed reductions in tyrosine hydroxylase expression that were comparable in subjects with both minimal motor features and PD.
INTERPRETATION: Minimal motor features in older adults may represent prodromal PD and identify at-risk individuals for testing putative neuroprotective interventions that could slow or prevent PD progression. Ann Neurol 2018;83:562-574.
© 2018 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29420861      PMCID: PMC5867270          DOI: 10.1002/ana.25179

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  40 in total

1.  A new strategy for analysis of phenotype marker antigens in hollow neurospheres.

Authors:  Michael L Moeller; S Dan Dimitrijevich
Journal:  J Neurosci Methods       Date:  2004-10-15       Impact factor: 2.390

Review 2.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

Review 3.  Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology.

Authors:  K Del Tredici; H Braak
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

4.  A stereological study of substantia nigra in young and old rhesus monkeys.

Authors:  H Pakkenberg; B B Andersen; R S Burns; B Pakkenberg
Journal:  Brain Res       Date:  1995-09-25       Impact factor: 3.252

5.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

6.  Nigral pathology and parkinsonian signs in elders without Parkinson disease.

Authors:  Aron S Buchman; Joshua M Shulman; Sukriti Nag; Sue E Leurgans; Steven E Arnold; Martha C Morris; Julie A Schneider; David A Bennett
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

7.  GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Authors:  Mickael Decressac; Ayse Ulusoy; Bengt Mattsson; Biljana Georgievska; Marina Romero-Ramos; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2011-06-28       Impact factor: 13.501

8.  Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.

Authors:  Yaping Chu; Katie Kompoliti; Elizabeth J Cochran; Elliott J Mufson; Jeffrey H Kordower
Journal:  J Comp Neurol       Date:  2002-08-26       Impact factor: 3.215

Review 9.  Trophic factor gene therapy for Parkinson's disease.

Authors:  Jeffrey H Kordower; Anders Bjorklund
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

10.  Incident parkinsonism in older adults without Parkinson disease.

Authors:  Aron S Buchman; Sue E Leurgans; Lei Yu; Robert S Wilson; Andrew S Lim; Bryan D James; Joshua M Shulman; David A Bennett
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

View more
  15 in total

1.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

2.  Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.

Authors:  Seok Jong Chung; Yang Hyun Lee; Han Soo Yoo; Young H Sohn; Byoung Seok Ye; Jungho Cha; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-12       Impact factor: 9.236

3.  Catechol-O-Methyltransferase Genotype, Frailty, and Gait Speed in a Biracial Cohort of Older Adults.

Authors:  Shannon Mance; Andrea Rosso; Joshua Bis; Stephanie Studenski; Nico Bohnen; Caterina Rosano
Journal:  J Am Geriatr Soc       Date:  2020-10-12       Impact factor: 5.562

4.  Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.

Authors:  Yaping Chu; Scott Muller; Adriana Tavares; Olivier Barret; David Alagille; John Seibyl; Gilles Tamagnan; Ken Marek; Kelvin C Luk; John Q Trojanowski; Virginia M Y Lee; Jeffrey H Kordower
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

5.  Fractures in the prodromal period of Parkinson disease.

Authors:  Alejandra Camacho-Soto; Anat Gross; Susan Searles Nielsen; Anna N Miller; Mark N Warden; Amber Salter; Brad A Racette
Journal:  Neurology       Date:  2020-04-28       Impact factor: 9.910

6.  Frequency of Parkinsonism and Parkinson Disease in African Americans in the Chicago Community.

Authors:  Meagan Bailey; Lisa M Shulman; Diane Ryan; Bichun Ouyang; Joshua M Shulman; Aron S Buchman; David A Bennett; Lisa L Barnes; Deborah A Hall
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-06-14       Impact factor: 6.053

7.  Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model.

Authors:  Diptaman Chatterjee; Mansi Bhatt; David Butler; Erwin De Genst; Christopher M Dobson; Anne Messer; Jeffrey H Kordower
Journal:  NPJ Parkinsons Dis       Date:  2018-08-22

Review 8.  The prodromes of Parkinson's disease.

Authors:  Richard Nathaniel Rees; Alastair John Noyce; Anette Schrag
Journal:  Eur J Neurosci       Date:  2018-12-05       Impact factor: 3.386

9.  Discordance in monozygotic Parkinson's disease twins - continuum or dichotomy?

Authors:  Alexander Balck; Max Borsche; Meike Kasten; Katja Lohmann; Philip Seibler; Norbert Brüggemann; Christine Klein
Journal:  Ann Clin Transl Neurol       Date:  2019-05-02       Impact factor: 4.511

10.  Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.

Authors:  Lu-Lu Bu; Yan Shen; Yi-Qi Liu; Yun Fan; Wen-Bo Yu; Dong-Lang Jiang; Yi-Lin Tang; Yu-Jie Yang; Ping Wu; Chuan-Tao Zuo; James B Koprich; Feng-Tao Liu; Jian-Jun Wu; Jian Wang
Journal:  Neurotherapeutics       Date:  2021-03-15       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.